That’s what happened with a recent study the JKTG Foundation supported, one that explored how iron-based nanoparticles could help detect and treat tumors more safely. This wasn’t hype. It was smart, specific science. And it’s the kind of work we’re proud to back.

You don’t usually associate spreadsheets with survival rates. But that’s exactly the connection Dr. Paul Macklin is exploring in our latest Driving Research episode.

There’s a habit in healthcare policy circles to treat hospitals as if they’re just another line item in the system. A vendor. A cost center. Something to cut, cap, or streamline. But hospitals are a lot more than that. They’re not just healthcare providers. They’re employers. Infrastructure anchors. Economic drivers. And in many communities, they’re the largest single source of jobs, stability, and social services. That’s not an argument for protecting the status quo. It’s a

If a project is safe, it will get funded. If it’s bold, uncertain, or disruptive, it probably won’t. That’s the problem. High-risk cancer research is exactly where the biggest breakthroughs often happen. But in most traditional funding models, the riskiest projects get pushed aside, not because they’re wrong, but because they don’t fit the system. This is where philanthropy comes in. And this is why the JKTG Foundation exists...